| Emerging drugs for hyperlipidemia. | |
| | |
MedLine Citation:
|
PMID: 20423271 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Elevated concentrations of low-density lipoprotein (LDL) cholesterol are associated with increased risk of coronary atherosclerosis, and morbidity and mortality from coronary heart disease (CHD). Lowering of LDL cholesterol leads to a reduction in cardiovascular morbidity and all-cause mortality in individuals at risk for cardiovascular events and patients with established CHD. The mainstays of lipid lowering therapy today are the HMG-CoA reductase inhibitors (statins); however, the residual risk of cardiovascular events amongst individuals treated with statins remains a major healthcare concern. AREAS COVERED IN THIS REVIEW: Emerging targets for lipid lowering therapy target pathways that regulate lipoprotein assembly, lipoprotein clearance and pro-atherogenic lipoprotein modification. These emerging drugs have novel mechanisms that include inhibition of lipoprotein assembly (antisense mRNA inhibitors of apolipoprotein B and microsomal transfer protein inhibitors), enhanced lipoprotein clearance (proprotein convertase subtilisin kexin type 9, thyroid hormone analogues), inhibition of pro-atherogenic lipoprotein remodeling (cholesterol ester transfer protein inhibitors (dalcetrapib, anacetrapib) and peroxisome proliferator activator agents (GFT-505, aleglitazar)) and inhibition of lipoprotein modification (heme oxygenase-1 inhibitor (succinobucol), phospholipase A(2) inhibitors (varespladib, darapladib)). WHAT THE READER WILL GAIN: A review of the most recent data on emerging drugs in the treatment of hyperlipidemia. TAKE HOME MESSAGE: With these medications, we will achieve more effective reductions in cardiovascular morbidity and mortality than achieved with current lipid lowering therapies. |
| | |
Authors:
|
Christos Paras; M Mahmood Hussain; Robert S Rosenson |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on emerging drugs Volume: 15 ISSN: 1744-7623 ISO Abbreviation: Expert Opin Emerg Drugs Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-18 Completed Date: 2010-11-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101135662 Medline TA: Expert Opin Emerg Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 433-51 Citation Subset: IM |
Affiliation:
|
SUNY Downstate Medical Center, Brooklyn, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cardiovascular Diseases / etiology, mortality, prevention & control Drug Delivery Systems* Drug Design Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, pharmacology, therapeutic use Hyperlipidemias / complications, drug therapy*, physiopathology Hypolipidemic Agents / pharmacology, therapeutic use* Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Hypolipidemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: eMedical Teacher.
Next Document: Is 'MILD' sleep-disordered breathing in women really mild?